References
- Bourne RR, Stevens GA, White RA, Smith JL, Flaxman SR, Price H, et al. Causes of vision loss worldwide, 1990–2010: a systematic analysis. Lancet Glob Health 2013;1:e339–e349.
- Marcus MW, Muskens RP, Ramdas WD, Wolfs RC, De Jong PT, Vingerling JR, et al. Cholesterol-lowering drugs and incident open-angle glaucoma: a population-based cohort study. PLoS One 2012;7:e29724.
- Evans WE. Pharmacogenomics: Translating Functional Genomics into Rational Therapeutics. Science 1999;286:487–491.
- Schwartz SG, Puckett BJ, Allen RC, Castillo IG, Leffler CT. Beta1-adrenergic receptor polymorphisms and clinical efficacy of betaxolol hydrochloride in normal volunteers. Ophthalmology 2005;112:2131–2136.
- Fuchsjager-Mayrl G, Markovic O, Losert D, Lucas T, Wachek V, Wachek V, et al. Polymorphism of the beta-2 adrenoceptor and IOP lowering potency of topical timolol in healthy subjects. Mol Vis 2005;11:811–815.
- Sakurai M, Higashide T, Takahashi M, Sugiyama K. Association between genetic polymorphisms of the prostaglandin F2alpha receptor gene and response to latanoprost. Ophthalmology 2007;114:1039–1045.
- Sakurai M, Higashide T, Ohkubo S, Takeda H, Sugiyama K. Association between genetic polymorphisms of the prostaglandin F2alpha receptor gene, and response to latanoprost in patients with glaucoma and ocular hypertension. Br J Ophthalmol 2014;98:469–473.
- Gao LC, Wang D, Liu FQ, Huang ZY, Huang HG, Wang GH, et al. Influence of PTGS1, PTGFR, and MRP4 genetic variants on intraocular pressure response to latanoprost in Chinese primary open-angle glaucoma patients. Eur J Clin Pharmacol 2015;71:43–50.
- McCarty CA, Berg R, Patchett R, Wilke RA, Burmester JK. Lack of association between polymorphisms in the prostaglandin F2alpha receptor and solute carrier organic anion transporter family 2A1 genes and intraocular pressure response to prostaglandin analogs. Ophthalmic Genet 2012;33:74–76.
- Hinz B, Rosch S, Ramer R, Tamm ER, Brune K. Latanoprost induces matrix metalloproteinase-1 expression in human nonpigmented ciliary epithelial cells through a cyclooxygenase-2-dependent mechanism. FASEB J 2005;19:1929–1931.
- Ocklind A. Effect of latanoprost on the extracellular matrix of the ciliary muscle. A study on cultured cells and tissue sections. Exp Eye Res 1998;67:179–191.
- Stjernschantz J, Selen G, Sjoquist B, Resul B. Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2 alpha analogue. Adv Prostaglandin Thromboxane Leukot Res 1995;23:513–518.
- Crowston JG, Lindsey JD, Aihara M, Weinreb RN. Effect of latanoprost on intraocular pressure in mice lacking the prostaglandin FP receptor. Invest Ophthalmol Vis Sci 2004;45:3555–3559.
- Ota T, Aihara M, Narumiya S, Araie M. The effects of prostaglandin analogues on IOP in prostanoid FP-receptor-deficient mice. Invest Ophthalmol Vis Sci 2005;46:4159–4163.
- Cheng-Bennett A, Poyer J, Weinkam RJ, Woodward DF. Lack of prostaglandin F2 alpha metabolism by human ocular tissues. Invest Ophthalmol Vis Sci 1990;31:1389–1393.
- Scherer WJ. A retrospective review of non-responders to latanoprost. J Ocul Pharmacol Ther 2002;18:287–291.
- Tamada Y, Taniguchi T, Murase H, Yamamoto T, Kitazawa Y. Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma. J Ocul Pharmacol Ther 2001;17:19–25.
- Ang A, Reddy MA, Shepstone L, Broadway DC. Long term effect of latanoprost on intraocular pressure in normal tension glaucoma. Br J Ophthalmol 2004;88:630–634.
- Souza MC, Martins CS, Silva-Junior IM, Chriguer RS, Bueno AC, Antonini SR, et al. NR3C1 polymorphisms in Brazilians of Caucasian, African, and Asian ancestry: glucocorticoid sensitivity and genotype association. Arq Bras Endocrinol Metabol 2014;58:53–61.
- Kraft ME, Glaeser H, Mandery K, Konig J, Auge D, Fromm MF, et al. The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost. Invest Ophthalmol Vis Sci 2010;51:2504–2511.